← Latest news 
Dr Reddy’s launches generic Semaglutide in Canada first G7 approval could widen GLP-1 access fast
Business
Published on 16 May 2026
Canada becomes the first G7 to approve it
Dr Reddy’s Laboratories has launched a generic Semaglutide injection in Canada for adults with type 2 diabetes, following Health Canada approval granted on April 28, 2026. The move makes Canada the first G7 nation to authorize Semaglutide, positioning the company among the earliest generics entrants in that market. The launch follows Dr Reddy’s recent introduction in India under the brand name Obeda. Supplied as a sterile prefilled pen, it is offered in 2 mg and 4 mg strengths.
- Dr Reddy’s received Health Canada Notice of Compliance on April 28, 2026
- Canada is the first G7 country to grant market authorization for Semaglutide injection
- The drug is indicated for once weekly treatment of type 2 diabetes
- It is used with diet and exercise to improve glycemic control
- Supplied as a sterile subcutaneous prefilled pen in 2 mg and 4 mg strengths
- Dosing includes 0.25 mg or 0.5 mg options from the 2 mg pen
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times